GlassScriptPhysician profile
Edwin L Petrik
NPI 1912916818
$778.57
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.78 | 2019-2020 | |
| Seagen INC. | $101.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.01 | 2019-2020 | |
| Kite Pharma, INC. | $88.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $79.09 | 2019 | |
| Pfizer INC. | $67.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.08 | 2019-2020 | |
| Janssen Biotech, INC. | $36.46 | 2019-2020 | |
| Lilly USA, LLC | $31.20 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.29 | 2019 | |
| Mylan Institutional INC. | $16.10 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.28 | 2019 | |
| Exelixis INC. | $11.42 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Petrik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.